Evidence Trace, complete trial record
In plain terms
In plain terms: Blood Flow Restriction Training has some human trial evidence supporting it, but the evidence is not yet strong enough for EBL to call it established. It is worth knowing about and worth discussing with your clinician.
Blood Flow Restriction Training
B
Supported: a good trial, backed by more
The endpoint this grade is based on: Objectively measured functional outcome
The evidence as the record states it
Anterior cruciate ligament (ACL) reconstruction rehabilitation: Hughes et al. (Sports Medicine, 2019; PMID 31301034), 28 patients, low-load blood flow restriction against standard heavy-load rehabilitation with a blinded assessor; Vieira de Melo et al. (Journal of Rehabilitation Medicine, 2022; PMID 36190389), 28 patients, greater quadriceps and hamstring strength against the same exercises without restriction; Hu et al. (Orthopaedic Journal of Sports Medicine, 2026; PMID 42428806), 9 randomized trials, 372 patients, quadriceps strength and Lysholm score improved while IKDC, pain and range of motion did not. Knee osteoarthritis: Machado et al. (2026; PMID 42367229), an overview of systematic reviews. Older adults: Zhang et al. (Scientific Reports, 2024; PMID 39558011). Strength and muscle at low loads in general, as background: Centner et al. (Sports Medicine, 2019; PMID 30306467), Lixandrão et al. (Sports Medicine, 2018; PMID 29043659) and Hughes et al. (British Journal of Sports Medicine, 2017; PMID 28259850). Each use carries its own letter.
PMID 36190389 PMID 31301034 PMID 42428806 PMID 42367229 PMID 39558011 PMID 30306467 PMID 29043659 PMID 28259850
Evidence by specific use
Post-ACL reconstruction rehabilitation
Grade B
PMID 31301034 PMID 36190389 PMID 42428806
Knee osteoarthritis
Grade C
PMID 42367229
Sarcopenia / older adults
Grade C
PMID 39558011
Longevity / mortality
Grade D
Why Grade B and not Grade A
Grade B reflects moderate human evidence -- typically a single strong trial, multiple smaller trials, or surrogate endpoint data without hard clinical outcome replication. To reach Grade A, Blood Flow Restriction Training would require at least one additional independent randomized trial demonstrating a hard clinical endpoint or objectively measured functional outcome in a comparable population.
What this grade covers and what it does not
Grade B on objectively measured strength after ACL reconstruction, resting on a meta-analysis of randomized trials (PMID 42428806) with supporting trials (PMIDs 31301034 and 36190389). Knee osteoarthritis (PMID 42367229) and sarcopenia (PMID 39558011) are graded C on their own evidence. Earlier meta-analyses found low-load training with blood flow restriction builds strength and muscle (Centner et al., 2019; PMID 30306467; Lixandrao et al., 2018; PMID 29043659; Hughes et al., 2017; PMID 28259850). WHAT THIS GRADE DOES NOT COVER: healthy untrained adults, where benefit is not established by these trials, and longevity or mortality, graded D because no human trial reports it.
What would move this grade
An independent randomized trial demonstrating a hard clinical endpoint -- mortality, major adverse event, or objectively confirmed functional improvement -- in an adequately powered sample, with results independently replicated, would support Grade A.
Citations withdrawn from this record
PMID 30536195, withdrawn July 2026Cited as "Centner 2019 meta-analysis (Sports Med)". The PMID resolves to "Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade glioma" (J Neurooncol).
PMID 28755103, withdrawn July 2026Cited as "Lixandrao 2018 meta-analysis (Sports Med)". The PMID resolves to Ralston, "The Effect of Weekly Set Volume on Strength Gain", correct journal, wrong paper.
PMID 41981492, withdrawn July 2026A randomized controlled trial PROTOCOL on sarcopenic dysphagia. A protocol has no results.
How to track whether this is working
Maximal voluntary contraction (MVC) or submaximal strength test at baseline and every 6 weeks. Limb girth at baseline and 8 weeks. Cuff pressure and placement at every session: the therapeutic window is narrow; too low achieves no BFR effect, too high risks nerve or vascular injury. The studied protocols typically use 20-30% of 1RM with 30/15/15/15 rep scheme.